Unique Features

  • Ability to combine the bone turnover markers with the established IDS-iSYS 25-Hydroxy Vitamin DS – aiding management of osteoporosis and other metabolic bone diseases
  • Exceptional sensitivity and reproducible results – providing a useful tool to identify non-adherent and non-responders to therapy
  • BAP levels are not affected by circadian variation – ease of sample collection, handling, and storage
  • BAP is cleared by the liver, not by the kidneys – levels are not affected by renal function
  • Reduced tube handling – wide variety of sample types supported
  • Clinically relevant measurement – as recommended in KDIGO guidelines
  • A complete clinical assay panel supporting bone disease management

The IDS-iSYS Ostase® BAP Assay is intended for the quantitative determination of bone-specific alkaline phosphatase (BAP), an indicator of osteoblastic activity, in human serum or plasma on the IDS-iSYS Multi-Discipline Automated System.

Results are to be used in conjunction with other clinical and laboratory data to aid the clinician in the management of post-menopausal osteoporosis and Paget’s disease.

Ostase® is a registered trademark of Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc.

Bone Alkaline Phosphatase (BAP) is a glycoprotein found on the surface of osteoblasts, which are the cells responsible for bone formation.

The metabolic activity of osteoblasts is reflected in the detected levels of BAP in serum. An accurate assessment of bone metabolism is critical for determining the severity of metabolic bone disease and responses to therapy.

Measurement of serum levels of BAP has been shown to be useful in evaluating patients with Paget’s disease, osteomalacia, primary hyperparathyroidism, renal osteodystrophy and osteoporosis.

Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD guidelines suggest that BAP is a marker to evaluate bone disease because markedly high or low values predict underlying bone turnover.1


Michelsen J et al. Bone. Reference intervals for serum concentrations of three bone turnover markers for men and women. 2013 Dec;57(2):399-404.

Schwarz P. et al. Paget’s disease of the bone after treatment with Denosumab: A case report. Bone 50 2012 1023–1025.